CN110404029B - 一种具有降血糖功效的组合物及其制备方法和应用 - Google Patents
一种具有降血糖功效的组合物及其制备方法和应用 Download PDFInfo
- Publication number
- CN110404029B CN110404029B CN201910757481.3A CN201910757481A CN110404029B CN 110404029 B CN110404029 B CN 110404029B CN 201910757481 A CN201910757481 A CN 201910757481A CN 110404029 B CN110404029 B CN 110404029B
- Authority
- CN
- China
- Prior art keywords
- composition
- parts
- concentrating
- water
- eluting
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 45
- 239000008280 blood Substances 0.000 title claims abstract description 30
- 210000004369 blood Anatomy 0.000 title claims abstract description 30
- 235000000346 sugar Nutrition 0.000 title claims abstract description 25
- 230000001603 reducing effect Effects 0.000 title claims abstract description 12
- 238000002360 preparation method Methods 0.000 title claims abstract description 10
- 239000003814 drug Substances 0.000 claims abstract description 28
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 21
- 244000089795 Clausena lansium Species 0.000 claims abstract description 17
- 235000008738 Clausena lansium Nutrition 0.000 claims abstract description 17
- 244000078118 Ilex latifolia Species 0.000 claims abstract description 17
- 235000008706 Ilex latifolia Nutrition 0.000 claims abstract description 17
- 229940079593 drug Drugs 0.000 claims abstract description 17
- 239000000284 extract Substances 0.000 claims abstract description 17
- 244000062241 Kaempferia galanga Species 0.000 claims abstract description 16
- 235000013421 Kaempferia galanga Nutrition 0.000 claims abstract description 16
- 244000302512 Momordica charantia Species 0.000 claims abstract description 16
- 235000009811 Momordica charantia Nutrition 0.000 claims abstract description 16
- 240000008042 Zea mays Species 0.000 claims abstract description 16
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 claims abstract description 16
- 235000002017 Zea mays subsp mays Nutrition 0.000 claims abstract description 16
- 235000005822 corn Nutrition 0.000 claims abstract description 16
- 238000000605 extraction Methods 0.000 claims abstract description 15
- 239000002994 raw material Substances 0.000 claims abstract description 14
- 235000009812 Momordica cochinchinensis Nutrition 0.000 claims abstract description 11
- 235000018365 Momordica dioica Nutrition 0.000 claims abstract description 11
- 238000001556 precipitation Methods 0.000 claims abstract description 8
- 239000011347 resin Substances 0.000 claims abstract description 8
- 229920005989 resin Polymers 0.000 claims abstract description 8
- 238000003809 water extraction Methods 0.000 claims abstract description 8
- 230000000694 effects Effects 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 11
- 239000000706 filtrate Substances 0.000 claims description 9
- 235000013305 food Nutrition 0.000 claims description 9
- IDGUHHHQCWSQLU-UHFFFAOYSA-N ethanol;hydrate Chemical compound O.CCO IDGUHHHQCWSQLU-UHFFFAOYSA-N 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 239000002904 solvent Substances 0.000 claims description 8
- 235000013361 beverage Nutrition 0.000 claims description 7
- 239000007787 solid Substances 0.000 claims description 7
- 238000001914 filtration Methods 0.000 claims description 6
- 239000002244 precipitate Substances 0.000 claims description 6
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 claims description 5
- 230000002218 hypoglycaemic effect Effects 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 238000001694 spray drying Methods 0.000 claims description 4
- 235000015895 biscuits Nutrition 0.000 claims description 3
- 235000009508 confectionery Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- 238000003756 stirring Methods 0.000 claims description 3
- 210000003813 thumb Anatomy 0.000 abstract description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 21
- 241000700159 Rattus Species 0.000 description 17
- 239000000243 solution Substances 0.000 description 13
- 238000012360 testing method Methods 0.000 description 13
- 230000000052 comparative effect Effects 0.000 description 11
- 201000001421 hyperglycemia Diseases 0.000 description 11
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 10
- 108010028144 alpha-Glucosidases Proteins 0.000 description 10
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 9
- 239000008103 glucose Substances 0.000 description 9
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 9
- 230000002401 inhibitory effect Effects 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- XUFXOAAUWZOOIT-SXARVLRPSA-N (2R,3R,4R,5S,6R)-5-[[(2R,3R,4R,5S,6R)-5-[[(2R,3R,4S,5S,6R)-3,4-dihydroxy-6-methyl-5-[[(1S,4R,5S,6S)-4,5,6-trihydroxy-3-(hydroxymethyl)-1-cyclohex-2-enyl]amino]-2-oxanyl]oxy]-3,4-dihydroxy-6-(hydroxymethyl)-2-oxanyl]oxy]-6-(hydroxymethyl)oxane-2,3,4-triol Chemical compound O([C@H]1O[C@H](CO)[C@H]([C@@H]([C@H]1O)O)O[C@H]1O[C@@H]([C@H]([C@H](O)[C@H]1O)N[C@@H]1[C@@H]([C@@H](O)[C@H](O)C(CO)=C1)O)C)[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O XUFXOAAUWZOOIT-SXARVLRPSA-N 0.000 description 5
- 229960002632 acarbose Drugs 0.000 description 5
- XUFXOAAUWZOOIT-UHFFFAOYSA-N acarviostatin I01 Natural products OC1C(O)C(NC2C(C(O)C(O)C(CO)=C2)O)C(C)OC1OC(C(C1O)O)C(CO)OC1OC1C(CO)OC(O)C(O)C1O XUFXOAAUWZOOIT-UHFFFAOYSA-N 0.000 description 5
- 238000006243 chemical reaction Methods 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 229960003105 metformin Drugs 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 4
- IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 4-nitrophenyl alpha-D-glucoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C([N+]([O-])=O)C=C1 IFBHRQDFSNCLOZ-ZIQFBCGOSA-N 0.000 description 3
- 230000003345 hyperglycaemic effect Effects 0.000 description 3
- 230000031700 light absorption Effects 0.000 description 3
- 229960004329 metformin hydrochloride Drugs 0.000 description 3
- OETHQSJEHLVLGH-UHFFFAOYSA-N metformin hydrochloride Chemical compound Cl.CN(C)C(=N)N=C(N)N OETHQSJEHLVLGH-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 238000005034 decoration Methods 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 235000013376 functional food Nutrition 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 235000016709 nutrition Nutrition 0.000 description 2
- 230000035764 nutrition Effects 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 210000000582 semen Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 206010059245 Angiopathy Diseases 0.000 description 1
- 201000001320 Atherosclerosis Diseases 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000004930 Fatty Liver Diseases 0.000 description 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 description 1
- 206010019708 Hepatic steatosis Diseases 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 208000001280 Prediabetic State Diseases 0.000 description 1
- 210000000683 abdominal cavity Anatomy 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000009098 adjuvant therapy Methods 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000013574 canned fruits Nutrition 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 230000007547 defect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 230000000378 dietary effect Effects 0.000 description 1
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 208000010706 fatty liver disease Diseases 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 238000003304 gavage Methods 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000003914 insulin secretion Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 238000000465 moulding Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 239000008057 potassium phosphate buffer Substances 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000031877 prophase Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 231100000240 steatosis hepatitis Toxicity 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- XPFJYKARVSSRHE-UHFFFAOYSA-K trisodium;2-hydroxypropane-1,2,3-tricarboxylate;2-hydroxypropane-1,2,3-tricarboxylic acid Chemical compound [Na+].[Na+].[Na+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O XPFJYKARVSSRHE-UHFFFAOYSA-K 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23G—COCOA; COCOA PRODUCTS, e.g. CHOCOLATE; SUBSTITUTES FOR COCOA OR COCOA PRODUCTS; CONFECTIONERY; CHEWING GUM; ICE-CREAM; PREPARATION THEREOF
- A23G3/00—Sweetmeats; Confectionery; Marzipan; Coated or filled products
- A23G3/34—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof
- A23G3/36—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds
- A23G3/48—Sweetmeats, confectionery or marzipan; Processes for the preparation thereof characterised by the composition containing organic or inorganic compounds containing plants or parts thereof, e.g. fruits, seeds, extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L2/00—Non-alcoholic beverages; Dry compositions or concentrates therefor; Preparation or treatment thereof
- A23L2/385—Concentrates of non-alcoholic beverages
- A23L2/39—Dry compositions
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/42—Cucurbitaceae (Cucumber family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/75—Rutaceae (Rue family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/899—Poaceae or Gramineae (Grass family), e.g. bamboo, corn or sugar cane
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9062—Alpinia, e.g. red ginger or galangal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation or decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/55—Liquid-liquid separation; Phase separation
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Botany (AREA)
- General Health & Medical Sciences (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Diabetes (AREA)
- Nutrition Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Inorganic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
本发明涉及中药组合物技术领域,公开了一种具有降血糖功效的组合物及其制备方法和应用。本发明所述组合物包括黄皮果皮、玉米须、大叶冬青、高良姜和苦瓜五种原料药的提取物。本发明选择黄皮果皮、玉米须、大叶冬青、高良姜和苦瓜五种药食同源的原料药进行提取,经过水提醇沉和大孔树脂富集,获得了一种具有由于常规药物的降血糖功效的组合物,其能够辅助治疗,或通过病人较长时间食用,改善其血糖水平,制备成功能性食品还能满足糖尿病人群的营养和口感需求。
Description
技术领域
本发明涉及中药组合物技术领域,具体涉及一种具有降血糖功效的组合物及其制备方法和应用。
背景技术
随着社会的发展与科技的进步,人们生活水平不断提高,人们的饮食结构也随之发生改变,糖类、蛋白质和脂肪的摄入量不断增加,而运动量却相对减少,高血糖等代谢性问题呈现不断上升的趋势,这也加剧了糖尿病、动脉粥样硬化、冠心病、脂肪肝等疾病发病率的升高。
高血糖是由于人体胰岛素分泌缺陷或共生物作用受损,或两者兼有引起的。是继肿瘤、血管病变之后,严重威胁人类健康的疾病。高血糖人群分为两个部分,一部分是有高血糖前期症状,但尚未被确定为糖尿病的人群,另一部分是糖尿病人群。高血糖作为一种症状并不能说明一定是糖尿病,高血糖指的是血糖高于正常值,但是没有达到糖尿病的诊断标准,人体正常血糖值为:空腹血糖<6.1,餐后两小时血糖<7.8,而糖尿病的诊断标准为:空腹血糖大于或等于7,餐后两小时大于或等于11.1,如果血糖值在正常和糖尿病之间的就是高血糖,也叫糖尿病前期。高血糖还有机会将血糖纠正,以后不用药物来控制血糖,对生活没有大的影响。而糖尿病确诊后,几乎是不可逆的。
据2016年世界卫生组织统计,我国糖尿病人已经超过1.1亿人,到2040年要超过1.5亿人。而尚未确定为糖尿病的高血糖人群约2亿多人,其中有0.4亿的人群要成为糖尿病病人。所以,降低高血糖人员的增加,是刻不容缓的大事,而且降低血糖也能改善二型糖尿病病人高血糖状况,辅助二型糖尿病的治疗。
目前糖尿病人的饮食需要进行严格的控制,不宜吃各种糖、固体饮料、蜜饯、水果罐头、饼干、甜面包及糕点等,而采用日常食物特别是“药食同源”原料的配伍,研制适合糖尿病以及高血糖人群食用且具有降血糖作用的食品,一方面能够辅助治疗,或通过病人较长时间食用,改善其血糖和水平,还能满足糖尿病人群的营养和口感需求。
发明内容
有鉴于此,本发明的目的在于提供一种具有降血糖功效的组合物,使其具备显著的降血糖功效;
本发明的另一个目的在于提供一种具有降血糖功效的组合物,使其具备显著的α-葡萄糖苷酶抑制活性。
本发明的另一个目的在于提供上述组合物的制备方法以及其在降血糖功能性食品中的应用。
为了实现上述目的,本发明提供如下技术方案:
一种具有降血糖功效的组合物,包括黄皮果皮、玉米须、大叶冬青(叶子)、高良姜和苦瓜五种原料药的提取物。
作为优选,各原料药重量份如下:
黄皮果皮50-100份、玉米须20-50份、大叶冬青20-50份、高良姜10-40份和苦瓜20-50份。
在本发明具体实施方式中,各原料药重量份可选择如下之一:
(1)黄皮果皮50份、玉米须20份、大叶冬青20份、高良姜10份和苦瓜20份。
(2)黄皮果皮100份、玉米须50份、大叶冬青50份、高良姜40份和苦瓜50份。
(3)黄皮果皮70份、玉米须40份、大叶冬青30份、高良姜30份和苦瓜50份。
在本发明具体实施方式中,上述五种原料药的提取物为经过水提醇沉后的提取物,更优选地的是经过水提醇沉以及大孔树脂富集和洗脱后的提取物。
对2型糖尿病大鼠的空腹血糖试验中,本发明所述组合物能够显著降低大鼠的空腹血糖,效果优于常规药物二甲双胍以及其他中药复方的对照组合物;同时,在检测α-葡萄糖苷酶抑制活性试验中,本发明组合物具备较高的α-葡萄糖苷酶抑制活性,效果明显优于常规药物阿卡波糖以及其他中药复方的对照组合物;上述两方面的试验表明本发明组合物能够有效降低空腹血糖和餐后血糖,具备明显的降血糖功效。
基于优异的试验结果,本发明提出了所述组合物在制备具有降血糖功效的食品中的应用;其中,所述食品包括但不限于固体饮料、饼干或糖果。
同时,本发明还提供所述组合物的制备方法,包括:
步骤1、将黄皮果皮、玉米须、大叶冬青、高良姜和苦瓜进行水提,浓缩,获得浓缩液;
步骤2、所述浓缩液加入乙醇进行醇沉,所得滤液浓缩获得浸膏;
步骤3、所述浸膏经大孔树脂富集和洗脱,获得所述组合物。
本发明具体实施方式中,步骤1为:
五种原料药经过粉碎后称重,加入3-10倍重量的水进行提取,提取温度为100-120℃,每次提取60-120min,提取3次;提取液混合后过滤,减压浓缩滤液至料液比1:2,得浓缩液。
在本发明具体实施方式中,步骤2为:
所述浓缩液按照1:1的比例,搅拌并加入乙醇,析出沉淀,过滤除去沉淀,滤液减压浓缩除去溶剂,得浸膏。
在本发明具体实施方式中,步骤3为:
所述浸膏经过大孔树脂富集,先用100%水洗脱,再用体积比3:7乙醇-水溶液进行洗脱,然后用体积比7:3乙醇-水溶液进行洗脱,合并后两次洗脱液,减压浓缩除去溶剂,再经过喷雾干燥,得到所述组合物。
由以上技术方案可知,本发明选择黄皮果皮、玉米须、大叶冬青、高良姜和苦瓜五种药食同源的原料药进行提取,经过水提醇沉和大孔树脂富集,获得了一种具有由于常规药物的降血糖功效的组合物,其能够辅助治疗,或通过病人较长时间食用,改善其血糖水平,制备成功能性食品还能满足糖尿病人群的营养和口感需求。
具体实施方式
本发明公开了一种具有降血糖功效的组合物及其制备方法和应用,本领域技术人员可以借鉴本文内容,适当改进工艺参数实现。特别需要指出的是,所有类似的替换和改动对本领域技术人员来说是显而易见的,它们都被视为包括在本发明。本发明所述组合物及其制备方法和应用已经通过较佳实施例进行了描述,相关人员明显能在不脱离本发明内容、精神和范围内对本文所述组合物及其制备方法和应用进行改动或适当变更与组合,来实现和应用本发明技术。
在本发明具体对比试验中,各组除应有的区别外,其余材料等试验环境均保持一致。
以下就本发明所提供的一种具有降血糖功效的组合物及其制备方法和应用做进一步说明。
实施例1:本发明所述组合物
1、原料药重量份
(1)黄皮果皮50份、玉米须20份、大叶冬青20份、高良姜10份和苦瓜20份。
(2)黄皮果皮100份、玉米须50份、大叶冬青50份、高良姜40份和苦瓜50份。
(3)黄皮果皮70份、玉米须40份、大叶冬青30份、高良姜30份和苦瓜50份。
2、水提醇沉法
五种原料药经过粉碎后称重,加入3-10倍重量的水进行提取,提取温度为100-120℃,每次提取60-120min,提取3次;提取液混合后过滤,减压浓缩滤液至料液比1:2,得浓缩液;
所述浓缩液按照1:1的比例,搅拌并加入乙醇,析出沉淀,过滤除去沉淀,滤液减压浓缩除去溶剂,得浸膏;
所述浸膏经过101大孔树脂富集,先用100%水洗脱,再用体积比3:7乙醇-水溶液进行洗脱,然后用体积比7:3乙醇-水溶液进行洗脱,合并后两次洗脱液,减压浓缩除去溶剂,再经过喷雾干燥,得到所述组合物。
实施例2:对2型糖尿病大鼠的影响
实验动物:SPF级健康雄性SD大鼠,6~8周龄,体质量(140±20)g。
试验药物:本发明实施例1组合物(配方1);
对比组:常规药物盐酸二甲双胍片;对比例1:玉米须、大叶冬青、高良姜和苦瓜;对比例2:黄皮果皮、玉米须、大叶冬青、高良姜、苦瓜和薏苡仁;对比例3:黄皮果皮、玉米须、大叶冬青、薏苡仁和苦瓜;对比例提取方法同
实施例1;
造模:大鼠喂养高糖高脂饲料4周后,对大鼠注射STZ制备2型糖尿病模型:造模前大鼠禁食不禁水12h,将STZ溶解于柠檬酸-柠檬酸钠溶液中,对大鼠进行腹腔注射,大鼠STZ的注射剂量为50mg/kg。1周后测定大鼠空腹血糖,血糖值≥9mmol/L作为模型大鼠。
分组给药:将糖尿病大鼠随机分为5组:模型组(蒸馏水,等体积),二甲双胍组(盐酸二甲双胍片,0.1g/kg),本发明实施例1组合物高、中、低剂量组(10g/kg,5g/kg,1g/kg),对比例1-3高剂量组(10g/kg),每组8只;另取8只正常大鼠作为空白组(蒸馏水,等体积)。连续灌胃给药28d,1次/d,给药期间空白组大鼠饲喂维持饲料,其余各组均饲喂高糖高脂饲料。所有大鼠禁食不禁水8h,剪尾尖取血,血糖仪测定空腹血糖值。结果如表1所示。
表1本发明所述固体饮料对2型糖尿病大鼠FBG的影响(n=8,mmol/L)
组别 | 给药前 | 给药后 |
本发明组合物高剂量组 | 23.60±4.21* | 6.65±2.23<sup>△▲■</sup> |
本发明组合物中剂量组 | 24.50±3.88* | 7.55±2.62<sup>△▲■</sup> |
本发明组合物低剂量组 | 23.45±4.11* | 8.24±2.80<sup>△▲■</sup> |
二甲双胍组 | 23.65±3.25* | 11.74±2.65<sup>△▲</sup> |
对比例1高剂量组 | 24.27±3.53* | 15.37±2.37<sup>△▲</sup> |
对比例2高剂量组 | 24.18±3.34 | 13.74±2.24<sup>△▲</sup> |
对比例3高剂量组 | 24.85±3.75* | 16.23±2.75<sup>△▲</sup> |
模型组 | 25.45±3.45* | 23.50±3.21* |
空白组 | 5.25±0.33 | 5.58±0.27 |
注:与空白组同期比较,*P<0.01;与模型组同期比较,△P<0.01;与本组治疗前比较,▲P<0.01;与二甲双胍组同期比较,■P<0.01;。
本发明所述固体饮料高、中、低剂量组(10g/kg,5g/kg,1g/kg)及阳性药二甲双胍组和三个对比例组,均对糖尿病大鼠具有较好的降血糖作用(P<0.01);其中,本发明所述组合物高、中、低剂量组相比二甲双胍药物具有更佳明显的效果;而其他三个对比例组效果低于常规药物二甲双胍。
同时,以本发明实施例1中其余两个配方为试验对象,试验结果与上述结果基本一致。
实施例3:体外α-葡萄糖苷酶抑制活性试验
试验药物:本发明实施例5固体饮料;
对比组:常规药物阿卡波糖;对比例1-3同实施例2;
试剂:阿卡波糖、α-葡萄糖苷酶、对硝基苯-α-葡萄糖苷(pNPG)、α-葡萄糖苷酶、磷酸氢钾、磷酸二氢钾、无水乙醇、二甲基亚砜和碳酸钠。
方法::0.1mmol/L的磷酸钾缓冲液(pH值6.8)0.5mL,再加入10mg/Lα-葡萄糖苷酶100μL,0.5mL样品溶液,混匀,37℃恒温15min后,加入2.5mmol/L pNPG 0.5mL,混匀后37℃恒温15min,最后加入1mL 0.2mol/L的Na2CO3溶液终止反应,于405nm波长下测OD值,重复3次,取平均值。实验重复3次。以阿卡波糖为阳性对照,分别检测不同质量浓度(0.05g/mL、0.1g/mL和0.5g/mL)的本发明实施例1组合物对α-葡萄糖苷酶的抑制活性,按(公式1)计算出抑制率,并计算其IC50值。结果如下表2所示。
酶活性抑制率=[A空白-(A样品-A背景)]/A空白×100% (公式1)
A空白:不加待测样品,只加入待测样品的溶剂,进行反应后的吸光值
A样品:加入待测样品反应后的吸光值
A背景:只加待测样品反应后的吸光值
表2本发明固体饮料的体外α-葡萄糖苷酶抑制活性试验效果
本发明组合物有明显的α-葡萄糖苷酶抑制活性作用,抑制效果均显著好于阳性对照组阿卡波糖。同时,以本发明实施例1中其余两个配方为试验对象,试验结果与上述结果基本一致。
以上所述仅是本发明的优选实施方式,应当指出,对于本技术领域的普通技术人员来说,在不脱离本发明原理的前提下,还可以做出若干改进和润饰,这些改进和润饰也应视为本发明的保护范围。
Claims (6)
1.一种具有降血糖功效的组合物,其特征在于,由黄皮果皮、玉米须、大叶冬青、高良姜和苦瓜五种原料药的提取物组成,各原料药重量份如下:
黄皮果皮50-100份、玉米须20-50份、大叶冬青20-50份、高良姜10-40份和苦瓜20-50份;
并经由以下制备方法制备获得:
步骤1、将黄皮果皮、玉米须、大叶冬青、高良姜和苦瓜进行水提,浓缩,获得浓缩液;
步骤2、所述浓缩液加入乙醇进行醇沉,所得滤液浓缩获得浸膏;
步骤3、所述浸膏经过大孔树脂富集,先用100%水洗脱,再用体积比3:7乙醇-水溶液进行洗脱,然后用体积比7:3乙醇-水溶液进行洗脱,合并后两次洗脱液,减压浓缩除去溶剂,再经过喷雾干燥,得到所述组合物。
2.权利要求1所述组合物在制备具有降血糖功效的食品中的应用。
3.根据权利要求2所述应用,其特征在于,所述食品为固体饮料、饼干或糖果。
4.权利要求1所述组合物的制备方法,其特征在于,包括:
步骤1、将黄皮果皮、玉米须、大叶冬青、高良姜和苦瓜进行水提,浓缩,获得浓缩液;
步骤2、所述浓缩液加入乙醇进行醇沉,所得滤液浓缩获得浸膏;
步骤3、所述浸膏经过大孔树脂富集,先用100%水洗脱,再用体积比3:7乙醇-水溶液进行洗脱,然后用体积比7:3乙醇-水溶液进行洗脱,合并后两次洗脱液,减压浓缩除去溶剂,再经过喷雾干燥,得到所述组合物。
5.根据权利要求4所述制备方法,其特征在于,步骤1为:
五种原料药经过粉碎后称重,加入3-10倍重量的水进行提取,提取温度为100-120℃,每次提取60-120min,提取3次;提取液混合后过滤,减压浓缩滤液至料液比1:2,得浓缩液。
6.根据权利要求4所述制备方法,其特征在于,步骤2为:
所述浓缩液按照1:1的比例,搅拌并加入乙醇,析出沉淀,过滤除去沉淀,滤液减压浓缩除去溶剂,得浸膏。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910757481.3A CN110404029B (zh) | 2019-08-16 | 2019-08-16 | 一种具有降血糖功效的组合物及其制备方法和应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201910757481.3A CN110404029B (zh) | 2019-08-16 | 2019-08-16 | 一种具有降血糖功效的组合物及其制备方法和应用 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN110404029A CN110404029A (zh) | 2019-11-05 |
CN110404029B true CN110404029B (zh) | 2021-09-21 |
Family
ID=68367747
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201910757481.3A Active CN110404029B (zh) | 2019-08-16 | 2019-08-16 | 一种具有降血糖功效的组合物及其制备方法和应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN110404029B (zh) |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN103710210A (zh) * | 2013-12-20 | 2014-04-09 | 芜湖中路实业有限责任公司 | 一种苦瓜玉米须保健米酒及其制备方法 |
CN109568420A (zh) * | 2017-09-29 | 2019-04-05 | 澳门大学 | 黄皮果核及其提取物在制备治疗糖尿病、肥胖症及高血脂的食品、保健品或药物中的用途 |
-
2019
- 2019-08-16 CN CN201910757481.3A patent/CN110404029B/zh active Active
Also Published As
Publication number | Publication date |
---|---|
CN110404029A (zh) | 2019-11-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR100645385B1 (ko) | 비만 억제용 조성물 | |
KR102262306B1 (ko) | 월경 전기 증후군 및 월경통 완화의 기능을 갖는 조성물 | |
JP3768795B2 (ja) | キサンチンオキシダーゼ阻害剤 | |
CN107580496B (zh) | 绞股蓝皂苷75的抗糖尿效果 | |
KR101427784B1 (ko) | 인삼 및 뽕나무 추출물을 유효성분으로 함유하는 항당뇨 조성물 | |
KR101811210B1 (ko) | 마가목 열매 추출물을 유효성분으로 하는 당뇨 질환 치료, 개선 또는 예방용 조성물 | |
CN109069562A (zh) | 多糖消化抑制剂 | |
JP2006160710A (ja) | 糖尿病の予防・治療用組成物およびその有効成分を含む健康食品 | |
KR101616811B1 (ko) | 짚신나물 추출물을 유효성분으로 포함하는 당뇨 및 당뇨합병증 예방 또는 개선용 조성물 | |
KR20160141027A (ko) | 아위버섯 물 추출물을 유효성분으로 함유하는 대사성질환의 예방 및 치료용 약학적 조성물 또는 건강기능성식품 | |
JP2013075874A (ja) | 血糖代謝改善剤 | |
CN110404029B (zh) | 一种具有降血糖功效的组合物及其制备方法和应用 | |
KR100293890B1 (ko) | 동아녹즙및그잔사를사용하여제조된체중및혈당조절용식품조성물및그제조방법 | |
KR20190066460A (ko) | 람부탄 씨앗 추출물을 유효성분으로 함유하는 당뇨병의 예방 또는 치료용 약학적 조성물 및 건강 기능 식품 | |
JP6273440B2 (ja) | Glp−1産生促進剤、dppiv阻害剤及びグルコース吸収阻害剤 | |
KR101222779B1 (ko) | 식용피 추출물을 유효성분으로 함유하는 당뇨병 예방 및 치료용 약학조성물 | |
KR102045847B1 (ko) | 관능성 및 항당뇨 활성이 증대된 옥미수·호박 가미 경옥고 | |
KR100895500B1 (ko) | 호노키올을 유효성분으로 함유하는 지방간 질환의 예방 및치료용 조성물 | |
KR20160091045A (ko) | 저속으로 추출한 석류주스를 유효성분으로 포함하는 간 기능 개선용 조성물 | |
TWI610681B (zh) | 一種黑蒜頭之抗血色素糖化及降血糖萃取物之製作方法 | |
JP2002053475A (ja) | 糖質分解酵素阻害剤およびそれを含有する飲食品 | |
KR20050102017A (ko) | 식초 가공 인삼제제를 이용한 제2형 당뇨병과대사증후군의 예방 및 치료용 조성물 | |
KR100473529B1 (ko) | 순기산 생약 복합제 추출물을 유효성분으로 함유하는당뇨병 예방 및 치료용 조성물 | |
KR20110111960A (ko) | 극성용매를 추출용매로 하여 추출한 연잎 추출물을 함유하는 혈당강화용 조성물 | |
KR100656086B1 (ko) | 인진쑥 추출물과 그를 함유한 식후과혈당 억제용 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant |